“Probabilistic atlases of post-treatment multi-parametric MRI scans reveal distinct hemispheric distribution of glioblastoma progression versus pseudo-progression”.

Promise and Reality of the Brave New World.. His talk titled, “Pathomics for Precision Oncology”, will be held on March 7th, 2021, 8:00am - 8:30am EST. 

Researchers discover biomarkers to identify lung cancer patients who could be made worse by same drugs that helps many others

For all the promise of AI-created precision medicines, observers say there’s a long way to go before they'll come to a drugstore near you. Anant Madabhushi, a biomedical engineering professor at Case Western Reserve University School of Medicine, said, "there is a lot of optimism but also a lot of hype" in the use of AI for precision medicine.

Inspirata: Upcoming fireside chat on Digital Pathology Innovation, being held virtually on March 2nd, featuring The Pathologist’s 2020 Power List, including Case Western Reserve University's 
Anant Madabhushi.

In an article titled, “Case Researchers Studying AI Use In Targeting Cancer Treatment,” author Anna Huntsman interviews CCIPD Director, Anant Madabhushi, PhD, about his work in precision medicine and recently-launched research agreement with the pharmaceutical company Boehringer Ingelheim. This collaboration will explore uses of AI to better identify therapies that are more likely to work for a specific patient. 

In a December 10th Reuters Health press release appearing on Medscape titled, “MRI-Based Nomograms May Predict Lymph Node Metastasis, Survival in Early Breast Cancer," author Marilynn Larkin quotes Nathaniel Braman, PhD, CCIPD alumnus, regarding how a machine learning MRI radiomic signature tool could help guide clinicians’ treatment decisions.

Anant Madabhushi, PhD, discusses how AI can be used to efficiently allocate healthcare resources by predicting response to treatment for COVID-19 patients.

The agreement is the third partnership in 2020 between the CCIPD and leading biopharmaceutical companies to advance artificial intelligence (AI) tools for disease diagnosis and prognosis, as well as predicting response to therapy. In April, the CCIPD entered into a contract with AstraZeneca and earlier in the year had inked a similar deal with Bristol-Myers Squibb Company.